Informazioni sull'atto

Autorizzazione allo Studio prot. AZ Cambria denominato ““A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant E

19/10/2023

20/10/2023

04/11/2023

918 del 19/10/2023

U.O.C. AFFARI GENERALI